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Introduction: Squamous cell carcinoma (SCC) is the secondmost common formof skin cancer in theUnited States.
The efﬁcacy of a pharmaceutically elegant radiotherapeutic bandage, previously described by us for application
against SCC of the skin, was tested for the ﬁrst time in vivo using a subcutaneous SCC mouse model and a thera-
peutically relevant radiation dose.
Methods: Female athymic nudemice were injectedwith human Colo-16 SCC cells subcutaneously and after eight
days (average tumor volume: 35 ± 8.6 mm3) received no treatment, or were exposed to non-radioactive or ra-
dioactive (92.5 ± 18.5 MBq) bandages for approximately 1 h (n= 10 per group). After treatment, tumors were
measured over ﬁfteen days, tumor volume ratios (TVRs) compared and histopathology performed.
Results: Fifteen days after treatment, the TVR of the radioactive bandage treatment group was 3.3 ± 4.5, while
TVRs of the non-radioactive bandage treatment and no treatment control groups were 33.2 ± 14.7 and
26.9 ± 12.6, respectively. At the time of necropsy, there was mild focal epidermal hyperplasia surrounding a
small area of epidermal ulceration in the radioactive bandage group. No other examined tissue (i.e., muscle,
liver, kidney, lung, spleen and heart) showed signiﬁcant lesions.
Conclusions: Our radiotherapeutic bandage exhibits promising efﬁcacy against SCC of the skin in a mousemodel.
It can be individually tailored for easy application on tumor lesions of all shapes and sizes, and could complement
or possibly replace surgery in the clinic.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is currently estimated that one in every ﬁve Americans will devel-
op skin cancer; most will be diagnosedwith non-melanoma skin cancer
(NMSC) [1], and the incidence of NMSC may increase by an estimated
50% by 2030 [2]. Most NMSCs develop on sun-exposed areas of the
body, such as the face and back of the hands [2]. The two major forms
of NMSCs are basal cell carcinoma (BCC) and squamous cell carcinoma
(SCC), and a recent study showed that up to approximately 400,000umor volume ratios.
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. This is an open access article undernew cases of SCC were diagnosed among the white population alone
in the US in 2012; the incidence data for other racial/ethnic groups
was limited [3].
Radiation therapy plays an irreplaceable role in current SCC therapy.
Therapy for SCC are generally selected based on the characteristics of
the patients and their neoplasm, such as a patient's age, surgical candi-
dacy, lesion size and location, level of differentiation and depth of inva-
sion [2]. When feasible, the treatment of choice is Mohs micrographic
surgery (MMS), which allows for excision of a lesion and its histological
examination, to achieve complete removal of the cancerous tissue [2].
However, when tumors are inoperable or patients cannot orwill not un-
dergo surgery, radiation therapy is commonly used as a primary and/or
adjuvant therapy for SCC [4]. Furthermore, key to the surgical removal
of SCC is the ability to achieve negative surgical margins [5],
i.e., complete removal of cancerous tissue; when surgical margins are
inherently compromised, radiation therapy is critical for the destruction
of SCC [4]. Radiation is also used to treat recurring lesions after a primary
surgical approach [6].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treatment of SCC [6], requires specialized equipment, requires multiple
in-patient sessions and, furthermore, the safety margin around the tu-
mors is high (~1–1.5 cm) causing more side effects on normal tissue
[7]. Another approach, brachytherapy, also requires special equipment
for application and, due to the nature of the technique, there is a risk
of radiation exposure to medical personnel who perform the therapy
[8]. A radiotherapeutic patch comprised of holmium-166 (166Ho) parti-
cles coated on the surface of a paper and laminated with a polyethylene
ﬁlm has been reported andwas used to suppress SCC in animals and in a
human trial, albeit with limited numbers of subjects in both studies
(n = 3 per group) [9]. Although it was mentioned that the particles,
which had a wide range of size (1–6 μm), were uniformly afﬁxed on
an adhesive tape, the uniformity of 166Ho in the constructwas not quan-
titated [9]. Moreover, stability of the patch after neutron-activationwas
not discussed; it is possible that the radionuclides on the surface could
ﬂake off, and therefore affect the efﬁcacy and cause safety hazards. To
overcome these limitations, we constructed and previously reported a
bandage containing 166Ho, which can be easilymanipulated and applied
externally to the skin; it was suggested that this device could be used for
selective radiotherapy of skin tumor lesions [10]. As previously report-
ed, the radiotherapeutic bandage used in this study was prepared
using uniform non-radioactive holmium-165 (165Ho)-containing gar-
net (165HoIG) nanoparticles and polyacrylonitrile (PAN) ﬁbers via
electrospinning and achieved good stability and uniformity of 166Ho dis-
tribution [10]. This technique allows us to embed radionuclide-
containing nanoparticles directly in the ﬁbers of the bandages, which
is an improvement over previously reported radioactive bandages/
patches/ﬁlms based on coatings, as it facilitates uniform distribution
throughout the construct [11]. Importantly, our previous study showed
that the prepared bandages were stable during and after neutron-
activation and emitted radiation uniformly throughout [10]; neutron-
activation can be performed off-site and then the material can easily
be shipped to a clinic with a precise radiation dose. Moreover, the
thickness of the electrospun bandages can be varied by controlling
parameters such as spinning duration, polymer concentration,
applied voltage, temperature and humidity [12]. The radiotherapeutic
bandage was prepared while non-radioactive and made radioactive by
neutron-activating 165Ho to 166Ho prior to treatment [10]. 166Ho,
which has a short half-life (26.8 h), emits both beta (β−) particles and
gamma (γ) photons. Its high-energy β− particles (1.84 MeV) [13] are
sufﬁcient to damage DNA in cancer cells just beneath the outermost
layer of the epidermis, while the γ photons (6.6% photon yield) [13]
can be used to easily quantify radiation dose of the bandage prior to
its application. The bandagewill be non-radioactive after approximately
ten half-lives, making its storage and disposal easy. The application of
the bandage during treatment of animals here was as easy as applying
a piece of tape onto the skin, which will minimize the risk of radiation
exposure of medical personnel if moved to the clinic. In the presentFig. 1. A (A) digital image, (B) SEM image and (C) ﬁber diameter distribution of the 165HoIG-con
piece of bandage was placed on weighing paper and the picture taken on a black background.study, the efﬁcacy of the radiotherapeutic bandage was tested in an
in vivomodel of SCC.
2. Materials and methods
2.1. Preparation of 165HoIG-containing PAN bandages
The 165HoIG-containing PAN bandages were synthesized as de-
scribed previously [10].
2.2. Neutron-activation of 165HoIG-PAN bandage
165HoIG-PAN bandages were then cut into small squares (average
weight: 10.3 ± 0.3 mg and size: 6–7 × 6–7 mm) and neutron-activated
in a 1 MW TRIGA® reactor at the Texas A&M nuclear science center.
Neutron-activation was carried out at a neutron ﬂux of 1.8 × 1013 neu-
trons/cm2·s for 1.33 h. Radioactivity from the bandages was quantiﬁed
before application using a 2470 Wizard2 automatic gamma counter
(Perkin Elmer, Shelton, CT).
2.3. Cells and animals
Human SCC Colo-16 cells were from the laboratory of Dr. Reuben
Lotan (University of Texas MD Anderson Cancer Center, Houston, TX)
[14] and authenticated via short tandem repeat (STR) DNA ﬁngerprint-
ing using the PowerPlex 16 HS System (Promega, Madison, WI) on
March 2014. The cells were grown in Keratinocyte-SFM medium
(Gibco® by Life Technologies, Grand Island, NY) supplemented with
3% fetal bovine serum and cultured under standard conditions in a hu-
midiﬁed, 37 °C, 5% CO2 atmosphere incubator. Female Hsd:Athymic
Nude-Foxn1numice (5–6weeks, ~20 g)were obtained fromHarlan Lab-
oratories (Indianapolis, IN). All animal procedures were performed fol-
lowing a protocol approved by the University of North Texas Health
Science Center Institutional Animal Care and Use Committee in accor-
dance with the NIH Guidelines.
2.4. Animal studies
The efﬁcacy of the radiotherapeutic bandages was tested in a xeno-
graft mousemodel for SCC. Onemillion Colo-16 cells were resuspended
in a total volume of 100 μL of PBS andMatrigel (Corning™, Bedford,MA)
(1:1) and then injected into the ﬂank of the left hind leg of each mouse.
Matrigel is often used to establish xenograft tumors in mice; however,
care must be taken to avoid gelation during the procedure. Eight days
after injection,when the tumorswere palpable (average tumor volume:
35 ± 8.6 mm3), the mice were assigned to one of the three following
groups (n = 10 per group): group A, no treatment control; group B,
non-radioactive bandage treatment control; and group C, radioactive
bandage treatment.taining polyacrylonitrile (PAN) non-radioactive bandage. The approximately 5 cm× 5 cm
Fig. 2. Tumor volume ratio (TVR) plotted against the number of days after treatment. §Threemice (one from group A and two from group B)were euthanized and tumors were harvested
due to high cumulative tumor score 12 days after treatment. *The average TVRof groupCwas signiﬁcantly different from group A (p b 0.05). **The average TVR of group Cwas signiﬁcantly
different from both groups A and B (p b 0.05).
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halation for 3 min and either non-radioactive bandage (group B) or ra-
dioactive bandage (group C) was attached onto the tumor using
NipEAZE™ tape (Owensboro, KY). An average radiation dose of
92.5 ± 18.5 MBq per mouse was delivered through the bandages in
group C. The bandages were removed after approximately 1 h and the
tumor volume was then monitored. The tumor size was measured
using a Vernier caliper and the tumor volume (V) was calculated
using the following equation:
V ¼ L W2
 
=2;Fig. 3. Top: Tumor-bearingmice in (A) no treatment, (B) non-radioactive bandage and (C) radio
mice in (A) no treatment, (B) non-radioactive bandage and (C) radioactive bandage treatment g
euthanized and tumors were harvested due to high cumulative tumor score 12 days after treawhere L is the length (large diameter) and W is the width of
the tumor (small diameter), both in millimeters. Tumor volume
ratios (TVRs) were calculated using tumor volume on the day of mea-
surement divided by tumor volume on the day of treatment (Day
0) [15]. Twelve days after treatment, two mice from group B and one
mouse from group A were sacriﬁced as their cumulative tumor scores
were high. Fifteen days after treatment, when all mice in the control
groups reached high cumulative tumor scores, all micewere euthanized
via CO2 inhalation followed by cervical dislocation. The efﬁcacy of the
bandages was determined by comparing the TVRs after treatment
among the groups.active bandage treatment groups 15 days after treatment. Bottom: Tumors harvested from
roups 15 days after treatment. §Threemice (one fromgroup A and two fromgroupB)were
tment.
Fig. 4. Representative histological evaluation of skin surrounding the tumor in mice from (A) no treatment, (B) non-radioactive bandage and (C) radioactive bandage groups.
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neys, lung, liver and spleen were collected in 10% neutral buffered for-
malin for histopathologic examination. The tissues were embedded in
parafﬁn and stained with hematoxylin and eosin, and were then exam-
ined for signs of radiation toxicity.Fig. 5. Representative histological evaluation of tissues from the no trea2.5. Statistical analysis
Statistical analysis was performed using SigmaPlot™ (Version 11.0;
Systat Software Inc., San Jose, CA). All the data were analyzed using
ANOVA on ranks followed by Dunn's post hoc analysis to compare thetment, non-radioactive bandage and radioactive bandage groups.
337B. Koneru et al. / Nuclear Medicine and Biology 43 (2016) 333–338difference among groups on each day. It was determined as a signiﬁcant
difference between values of different groups when p b 0.05.
3. Results
In this study, polyacrylonitrile (PAN) (molecularweight: 150,000mol/g)
solution containing 165HoIG nanoparticles (33%w/w) was electrospun to
produce a ﬂexible bandage (Fig. 1 A), as described previously [10]. SEM
image of the electrospun ﬁber mat is shown in Fig. 1 B. As shown in the
histogram, the average diameter of nanoﬁbers is 198 ± 45 nm (Fig. 1 C).
In order to test the efﬁcacy of the bandage, Fig. 1 A, an in vivo efﬁcacy
study was carried out in a xenograft mouse model. Female athymic
nude mice were injected with one million human SCC cells (Colo-16)
subcutaneously into their left ﬂank. The mice were then divided into
three groups (n = 10 per group) and received either no treatment
(group A), or non-radioactive (group B) or radioactive bandage treat-
ment (group C). After neutron-activation, the 166Ho content in the ban-
dages was 20.7 ± 4.4% w/w, calculated based on the radioactivity of
each piece of bandage measured using a gamma counter, which is sim-
ilar to that of the previously reported radiotherapeutic bandages [10].
An average radiation dose of 92.5 ± 18.5MBq permouse was delivered
through the bandages in group C.
To evaluate the efﬁcacy of the radiotherapeutic bandage (group C),
TVRs were calculated and compared among the radioactive treatment
group and the other two control groups (groups A and B). In Fig. 2, the
comparison of TVRs among groups A, B and C on 1, 2, 3, 5, 7, 9, 12 and
15 days after treatment is shown. On day 2, the TVR of group C
(1.0 ± 0.4) was signiﬁcantly lower than that of group A (1.9 ± 0.8).
From day 3 up to sacriﬁce on day 15, the TVR of group Cwas signiﬁcant-
ly lower than that of both groups A andB. The overall tumor growth rate
was lower in group C compared to groups A and B as indicated by the
increase in TVRs with time (Fig. 2). Fig. 3 shows the tumor burden of
the mice on the day they were euthanized. When high cumulative
tumor scores were reached (rapid weight loss, signs of impaired mobil-
ity and/or ulcerated tumor), one mouse (A10) from group A and two
(B9 and B10) from group B were euthanized on day 12. All other mice
(A 1–9, B1–8 and C1–10) were sacriﬁced on day 15 after treatment, as
the mice in groups A and B reached high cumulative tumor scores (im-
paired mobility, weight loss and/or ulcerated tumors). It is obvious that
the tumor burden of groups A and B was higher compared to that of
group C. On day 15, three (C1, 2 and 4) out of tenmice in the radioactive
bandage treatment group had complete tumor elimination with anoth-
er one having a very small tumor (C3); the other six in the same group
had signiﬁcantly smaller volume compared to the control groups; the
TVR of group C was only 3.3 ± 4.5, while TVRs of groups A and B were
26.9 ± 12.6 and 33.2 ± 14.7, respectively.
The non-radioactive bandage (group B) showed no signiﬁcant effect
on the tumor growth (Fig. 2) compared to the no treatment group
(group A) and there were no gross or histologic abnormalities of the
skin due to the non-radioactive bandage (Fig. 3). The radioactive ban-
dage group (group C) showed slight skin damage, which started on
day 5, but the damage was recovering without any intervention. At
the time of necropsy, there was mild focal epidermal hyperplasia sur-
rounding a small area of epidermal ulceration (Fig. 4). All other tissues
in the control group, non-radioactive bandage group and radioactive
bandage group showed no signiﬁcant lesions (Fig. 5).
4. Discussion
The incidence of NMSCs is increasing rapidly [2,3,16]. SCC, a form of
NMSC, is being diagnosed widely [3], but very little is being done to im-
prove its therapy. Radiation therapy is used as primary and/or adjuvant
for the treatment of SCC [6]. External beam therapy,which is often used,
requires specialized equipment and can cause damage to surrounding
healthy tissues. We previously reported a radiotherapeutic bandage
that may be useful for the treatment of SCC in clinic [10]. The bandageconsists of 166Ho as a source of radiation,which is both a β− and γ emit-
ter and has a short half-live. These bandages were shown to be stable
and emit uniform radiation throughout [10]. The shape of the
radiotherapeutic bandage can be manipulated as per the tumor size
and therefore helps in reducing the healthy tissue damage. The ban-
dages are prepared while non-radioactive and are made radioactive by
neutron-activation.
Previously, Jeong and co-workers prepared rhenium-188 (188Re)-
labelled nitrocellulose paper and tested its efﬁcacy in a syngeneic
mouse model for SCC [17]. When natural rhenium is neutron-
activated, two radioactive isotopes, rhenium-186 (186Re) and 188Re,
are produced, which makes dosimetry difﬁcult. Enriched rhenium can
be used; however 188Re is typically produced via decay of tungsten-
188 (188W), which is produced through a double neutron capture reac-
tion on tungsten-186 (186W) and requires a 188W/188Re generator [18].
The only one stable isotope of natural holmium is 165Ho, so only 166Ho is
produced via simple neutron-activation. Furthermore, while the 188Re
paper was prepared using generator-eluted 188Re, whichmight compli-
cate GMP, our bandage is prepared when non-radioactive and then
made radioactive just before therapy. As stated earlier, Lee and co-
workers prepared a 166Ho skin patch, which was successfully used to
treat chemically induced SCC in mice, and three SCC patients [9]. How-
ever, our bandage represents a more stable and fully characterized con-
struct suitable for immediate transition into the clinic [10].
Here, the overall tumor growth rate was signiﬁcantly lower in the
radioactive bandage group compared to the no treatment and non-
radioactive bandage groups. Each mouse in the radioactive bandage
group received an average dose of 92.5 ± 18.5 MBq for approximately
1 h, and the β− particles emitted from 166Ho have a range of maximum
8.7 mm (average 2.1 mm) in human tissues [9,19]. According to a do-
simetry estimation by Lee and coworkers on the 166Ho skin patch [9]
and by Mowlavi and coworkers on a similar conﬁguration [20], expo-
sure to 92.5 MBq 166Ho for 1 h could result in 31 Gy of radiation at
1.5 mm below the skin and 14 Gy at 2.5 mm, but dramatically reduced
to only 1.9Gy at 4.5mmdepth. Thus, the dose used in this report is ther-
apeutically relevant [7], and this type of treatment is useful for lesions of
approximately 2.1 mm in depth; precise radioactivities can be obtained
by increasing or decreasing the length of neutron-activation. The radio-
active bandage caused only slight skin damage. Similar skin damage
was observed by Lee and coworkers and Jeong and coworkers, when
their 166Ho patch and 188Re paper were used, respectively. Their mice
recovered from skin damage in 7 days [9,17].
5. Conclusions
Current standard of care radiation requires the use of cumbersome
equipment, specialized instrumentation and facilities, whereas the ban-
dages described here could potentially be applied with nothing more
than a lead band to cover it, while the patient sits in an ofﬁce room.
These bandages can be individually tailored for easy application on
tumor lesions of all shapes and sizes, and manufactured on a large
scale, making them an especially attractive material. Thus, the
radiotherapeutic bandage described here is an innovative approach to
treat SCC in the clinic.
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